By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: New Documentary Film Shines Light On Physical And Emotional Impact Of COPD 9/21/2017 9:33:07 AM
Boehringer Ingelheim Release: CHMP Positive Opinion To Include RE-CIRCUIT Data For Atrial Fibrillation Patients Undergoing Catheter Ablation In Pradaxa Summary Of Product Characteristics 9/18/2017 7:15:32 AM
IPF World Week 2017: Boehringer Ingelheim Helps Healthcare Professionals To "Listen For The Sounds Of IPF" 9/18/2017 6:20:44 AM
Boehringer Ingelheim Receives Positive CHMP Opinion For Adalimumab Biosimilar CYLTEZO 9/15/2017 6:14:11 AM
Boehringer Ingelheim Release: Safety And Efficacy Results From The INJOURNEY Trial Investigating OFEV (Nintedanib) With Add-On Pirfenidone Provide New Data To Support Nintedanib’s Key Role In IPF 9/11/2017 6:22:20 AM
Pharmaxis (PXS.AX) Boehringer Ingelheim Is Initiating Phase Iia Study For The Development Of A New Treatment For Diabetic Retinopathy - A Leading Cause Of Vision-Loss 9/8/2017 8:45:21 AM
Boehringer Ingelheim And Gubra Collaborate To Develop Next Generation Obesity Treatments 9/7/2017 7:00:03 AM
Inventiva Announces Exercise Of Option By Boehringer Ingelheim To Jointly Develop Potential New Treatments For Idiopathic Pulmonary Fibrosis (IPF) 9/5/2017 10:48:27 AM
Boehringer Ingelheim Release: Pradaxa (Dabigatran Etexilate) Dual Therapy Showed Lower Rates Of Major Bleeding Versus Triple Therapy With Warfarin In Atrial Fibrillation Patients Undergoing Stent Placement 8/28/2017 8:16:47 AM
Boehringer Ingelheim Release: RE-DUAL PCI Results Offer Favorable New Safety Data On Pradaxa 8/28/2017 6:39:07 AM